Although UBE3A-del has significant predictive value for NSCLC, the limitation of this study is that we only used bioinformatics to analyze the predictive value of UBE3A-del in only the immunotherapy of NSCLC, which is unknown for other tumors, and lacked verification in experiments and clinics. This evidence concerns the gene UBE3A and non-small cell lung carcinoma.